Prot #20110265: A Phase 1b/3, Multicenter, Trial of Talimogene Laherparepvec in Combination With Pembrolizumab (MK-3475) for Treatment of Unresectable Stage IIIB to IVM1c Melanoma (MASTERKEY-265)

Project: Research project

Project Details

StatusActive
Effective start/end date9/29/169/29/22

Funding

  • Amgen, Inc. (Prot #20110265)